Novartis
Novartis has sought to distance Narasimhan from the contract, saying he had nothing to do with it.
GSK last week quit the race to buy Pfizer’s consumer healthcare business, endangering an auction the U.S. drugmaker hoped would bring in as much as $20 billion.
